Showing results (31-40 of 131) with videos related to
Sort By:
Pageof 14
Hospital Pharmacy|August 7, 1989
An analysis of 1986 drug procurement practices in hospitals within the United StatesR T Smolarek, M F Powell, D K Solomon, et al.Antimicrobial Agents and Chemotherapy|February 22, 2001
Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic modelE A Coyle, M J RybakAntimicrobial Agents and Chemotherapy|February 13, 2001
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetationsR L Akins, M J RybakDrugs|February 24, 2001
Emergence of methicillin-resistant Staphylococcus aureus with intermediate glycopeptide resistance: clinical significance and treatment optionsM J Rybak, R L AkinsAntimicrobial Agents and Chemotherapy|March 1, 1996
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clotsS M Palmer, M J RybakAntimicrobial Agents and Chemotherapy|May 1, 1996
Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection modelD M Cappelletty, M J RybakExpert Opinion on Emerging Drugs|July 2, 2005
Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteriaG W Kaatz, M J RybakAntimicrobial Agents and Chemotherapy|April 19, 2000
Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection modelJ R Aeschlimann, E Hershberger, M J RybakAntimicrobial Agents and Chemotherapy|August 3, 1999
Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureusJ R Aeschlimann, E Hershberger, M J RybakPageof 14